EFFECT OF NE-100, A NOVEL SIGMA-RECEPTOR LIGAND, ON PHENCYCLIDINE-INDUCED COGNITIVE DYSFUNCTION

被引:31
作者
OGAWA, S [1 ]
OKUYAMA, S [1 ]
ARAKI, H [1 ]
OTOMO, S [1 ]
机构
[1] TAISHO PHARMACEUT CO LTD,CTR RES,DEPT PHARMACOL,SAITAMA 330,JAPAN
关键词
NE-100; SIGMA RECEPTOR; PHENCYCLIDINE; COGNITION; NEUROLEPTIC; (RAT);
D O I
10.1016/0014-2999(94)90517-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride (NE-100) is a selective and potent a receptor ligand. We investigated the effects of NE-100 on phencyclidine (PCP)-induced cognitive dysfunction in rats in a water maze task. NE-100 significantly shortened the PCP-induced prolonged swimming latency as did 1-(cyclopropylmethyl)-4-[2'(4''-fluorophenyl)-2'-oxoethyl]-piperidine monohydrobromide (Dup 734), 4-[2'-(4''-cyanophenyl)-2'-oxoethyl]-1-(cyclopropylmethyl)piperidine (XJ 448), alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (BMY 14802) and rimcazole, all of which are sigma receptor ligands and possibly antagonists. Ritanserin, a 5-HT2 receptor antagonist, also showed a tendency to shorten swimming latencies. Latencies of haloperidol-, cis-N-(1-benzyl-2-methyl-pyrrolidin-3-yl)-2-methoxy-5-chloro-4-methylaminobenzamide (YM-09151-2)- and sulpiride-, dopamine D-2 receptor antagonists, treated groups did not differ from that seen in the PCP-treated group. Thus, PCP-induced cognitive dysfunction may be improved by a receptor ligands.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 59 条
[41]   EFFECTS OF NMDA RECEPTOR ANTAGONISTS AND SIGMA-LIGANDS ON THE ACQUISITION OF CONDITIONED FEAR IN MICE [J].
SANGER, DJ ;
JOLY, D .
PSYCHOPHARMACOLOGY, 1991, 104 (01) :27-34
[42]  
SAYKIN AJ, 1991, ARCH GEN PSYCHIAT, V48, P618
[43]   SIGMA-RECEPTORS IN SCHIZOPHRENIC CEREBRAL CORTICES [J].
SHIBUYA, H ;
MORI, H ;
TORU, M .
NEUROCHEMICAL RESEARCH, 1992, 17 (10) :983-990
[44]  
Snyder S H, 1989, J Neuropsychiatry Clin Neurosci, V1, P7
[45]  
Strauss W H, 1991, Eur Neuropsychopharmacol, V1, P101, DOI 10.1016/0924-977X(91)90710-C
[46]  
STURGEON RD, 1979, EUR J PHARMACOL, V59, P169
[47]  
TAM SW, 1992, J PHARMACOL EXP THER, V263, P1167
[48]   MEMORY IMPAIRMENT IN SCHIZOPHRENIA - ITS EXTENT, AFFILIATIONS AND NEUROPSYCHOLOGICAL CHARACTER [J].
TAMLYN, D ;
MCKENNA, PJ ;
MORTIMER, AM ;
LUND, CE ;
HAMMOND, S ;
BADDELEY, AD .
PSYCHOLOGICAL MEDICINE, 1992, 22 (01) :101-115
[49]   NEGATIVE SYMPTOMS AND VISUAL BEHAVIOR IN DSM-III-R PROGNOSTIC SUBTYPES OF SCHIZOPHRENIFORM DISORDER [J].
TROISI, A ;
PASINI, A ;
BERSANI, G ;
DIMAURO, M ;
CIANI, N .
ACTA PSYCHIATRICA SCANDINAVICA, 1991, 83 (05) :391-394
[50]  
TSUNGPING SU, 1991, EUR J BIOCHEM, V200, P633